The Latest Cardiac and Vascular News
Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking […]
MARLBOROUGH, Mass., Sept. 3, 2020 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective […]
Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive data for two devices […]
MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ — Today, Boston Scientific (NYSE :BSX ) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease […]
